Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Clinical trial NCT05005975 · RECRUITING
Trial details
- NCT number
- NCT05005975
- Sponsor
- Tanabe Pharma America, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-10
- Primary completion
- 2027-12-01
- Enrollment
- 301
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.